Literature DB >> 6806170

Hepatic veno-occlusive disease after high-dose mitomycin C and autologous bone marrow transplantation therapy.

M R Gottfried, O Sudilovsky.   

Abstract

Three cases of veno-occlusive disease of the liver were diagnosed in four autopsied patients who had received high-dose mitomycin C therapy followed by autologous bone marrow transplantation, and the pathologic finding are reported. Review of 27 liver, examined post mortem, of patients receiving other high-dose chemotherapeutic regimens, 15 of them with subsequent autologous bone marrow transplantation, revealed no evidence of veno-occlusive disease. Veno-occlusive disease may now become a dose-limiting factor in the use of the combined high-dose mitomycin C-bone marrow transplantation therapy. Attention is also drawn to the increasing number of veno-occlusive disease cases being reported in associated with alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6806170     DOI: 10.1016/s0046-8177(82)80008-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Pulmonary veno-occlusive disease after chemotherapy.

Authors:  B K Knight; A G Rose
Journal:  Thorax       Date:  1985-11       Impact factor: 9.139

2.  Pulmonary veno-occlusive disease after chemotherapy.

Authors:  D A Ellis; S J Capewell
Journal:  Thorax       Date:  1986-05       Impact factor: 9.139

Review 3.  Intestinal and liver toxicity of antineoplastic drugs.

Authors:  G B McDonald; N Tirumali
Journal:  West J Med       Date:  1984-02

4.  Focal veno-occlusive lesions following metastasis of cancer in the liver with special reference to obstruction of lymphatics in hepatic veins.

Authors:  Y Shibayama; K Hashimoto; K Nakata
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 5.  Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.

Authors:  J Ludwig; R Axelsen
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.